Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
With the news of a upturn in cases in the Leicester area, and the fact that the local hospital was involved in the SNG trial, would hope that we would have a good uptake for the Home trial - good opportunity to boost the patient figures
SGD - Link Below
https://patents.google.com/patent/US7871603
Rich - I get that....but couldn’t really understand the logic of unblinding the COPD trial data after they suspended the trial. For a number of weeks it was just there in the background waiting to be picked up again at a future point. Then we learn of the unblinding - there needed to have been some factor to have brought that about....
Green fish - don’t underestimate the value of the COPD data and results - I can see a large pharma having developed a M&A business case for that alone....massive market that will be there long after Covid 19 has been derisked. Add in the current virus ‘attraction’ and you have a juicy deal but IMO the embedded value of SNG is with COPD - and there has to be a compelling reason to unblind that trial data when it happened
Hardcore 1 - thanks for your anecdotal feedback which is always useful and welcome. Also, it struck a chord as I had considered this previously - how medical staff themselves feel on a double blinded trial when it seems increasingly obvious to them which patients are on which treatment if the responses become so evident - the frustration at not being able to widen the offer. But then that’s the objective of the trial I guess....and to ensure that it’s not the placebo that provides the benefit!
MaverickD - Mmmmm......market clearly disagrees with you. Clearly room to strip out a huge amount of duplicated infrastructure costs between the two businesses and drive up bottom line and market value
Yes CT - was categoric in saying July for Covid hospital, then ‘Summer’ for COPD - therefore now wondering if COPD will come out after the hospital results....or around the same time?! That’s at least the second iv where he has been specific on summer for COPD
Hi CT
I think hospital will be a mixed bag - it could be 20-30% improved with SNG over the placebo - but the nature of the virus timeline indicates that effectiveness is probably less than in the early stages. However, even that percentage should be considered as positive - and suggestions are that in conjunction with other therapies might collectively lead to a much more positive outcome. And I’m judging ‘success’ against the benchmark of the recent dexamethasone results. For me the game changer should be the Home treatment - that could change the therapy landscape for further attacks and alleviate pressure on primary care.
Also, I was originally drawn to this share for its COPD angle as I have a relative who suffers badly and who gets knocked back every winter - yet the financial prospects (short term) of this share seem drawn to Covid.
This share is set up to be played for a few weeks to come IMO.....ideal for traders and IIs whose strategy is to dump stock (especially where acquired for a knock down price).
My expectation on results:
COPD - will be positive - it’s what the drug is set up to do - results will price effectiveness. Results announced within the next 7-10 days. SP will rise and then fall back whilst traders trade and IIs continue to sell within selected ranges
Hospital Covid results mid-July - ok but not ‘spectacular’..,.effective to a point (Leicester Dr predicted some ‘small but welcome benefit from existing therapies’). Again price will rise leading up and on results and then fall away as traders and IIs again take advantage.
Home Results is the unknown for release as the extension should positively impact the availability timeline. Expectation is that they should be more positive than hospital and the price will respond accordingly along with any announcement on partnering / supply / licensing / accelerated approval etc. At that point SP may start to reward those PIs that have stayed on board. However I think we are some weeks away from that point and meanwhile there will be all sorts of games being played.
Part of me thinks they should have kept all the results back to the end point - would have removed or diminished some of the volatility fuel on which AIM stocks and MMs thrive
DT - you didn’t post in good faith - you bought some AVCT and came here to deramp and push SNG holders onto AVCT based on pure ignorance - and FYI I also hold some AVCT but your claims and forecasts are complete Bol....s When it comes to both!
Interesting piece on US scientists wanting to see the data evidence behind the claims of the U.K. ‘wonder drug’ - which is why SNG’s insistence on keeping the focus on data is key
https://apple.news/AqMBA_nbWRoO2yPcpdLRKgw
Listening to Matt Han**** and the scientists yesterday and this morning, we are obviously now moving to a stage of preparing for later this year and into the winter. A likely 2nd wave of Covid, together with the usual season of influenza and other seasonal viruses, the priority will be to have a coherent set of defences to protect the NHS at all stages of the virus timeline.
The ‘wonder drug’ yesterday provides some additional relief to patients at the extreme of the timeline and therapies will gradually come forward that are more effective at earlier stages. For SNG the prospects should be very good - it’s whole being is focussed on adding a defence to more vulnerable patients against seasonal viruses (which would include Covid) - the trial results will feature over coming weeks. From what we know, based on over a decade of solid work and research by the SNG team, we should be confident - this is not a repurposed drug....it’s what it was developed to do.
And what do we think the CEO has been doing for the last 2 months....sitting behind his desk waiting for the data to land? I strongly suspect that there have been a huge number of commercial discussions - from licensing through to potential M&A....all aimed at hitting the ground running - it’s what he’s paid to do. The big pharma s will have had SNG on their radar - it’s also what they do.
Oh - and the post title no way reflects my view on the SP! GLA
There’s a 2017 strategy document online for NHS Wales which highlights average per night cost for a Level 3 Intensive Care bed at £1932 compared with a general ward bed nightly cost of £413....some of those severely sick COVID patients that could spend around 8 weeks there would therefore cost >£100k
For me the following reasons:
1). Trying to complete the COPD trial in the midst of a pandemic and potential crossover of patients would have been a distraction to key hospital resources
2). Proof of safety and effectiveness against an aggressive virus attacking the lungs is what SNG is all about - great opportunity
3). Covid provided a fast-track opportunity to have the product and corporate feature highly on the radar of both health and finance communities
4). Success would actually underpin and reinforce all of the inherent value believed to be within the therapy for COPD / asthma / fibrosis
5). Potential exit strategy for some of the long-serving members of the team
In the words of the CEO “this is our time”
I have a much smaller holding in AVCT than in SNG. Just watched a webinar with the former and because the CEO informed that the results for the POC antigen test would be another couple of weeks, within minutes the sp is down as a result. These companies are being held hostage to days here....too much hot money flying in and out!